Bolsamania - The website of the stock exchange and the stock markets

Bankinter Market Consensus It is an exclusive licensing agreement for the development and marketing of this drug in Japan. PharmaMar will receive an initial payment of 22 million euros plus two-digit royalties on net sales and, other payments for the fulfillment of various clinical, regulatory or commercial milestones for a total of up to 31 million euros additional. PharmaMar will supply Lurbinectedin to Merck for clinical and commercial use. …

Under the terms of the agreement, PharmaMar will receive an initial payment of 22 million euros. PharmaMar is entitled to double-digit royalties on net sales, as well as to receive other payments for the fulfillment of various clinical, regulatory or commercial milestones for a total of up to 31 million additional euros. PharmaMar will supply Lurbinectedin to Merck for clinical and commercial use. "We are delighted to partner with Merck, to boos…